Life Sciences Archive » February, 2026

Life Sciences - February, 2026

253 articles

• PetMed, Elanco, Tractor Supply Settle Flea & Tick Med Claims
• Fed. Circ. Urged To Undo Attys' DQ In Patent Fight
• AI-Focused Generate Biomedicines Prices $400M IPO
• Bristol-Myers Campus Sale Suit Sent Back To NJ
• 3rd Circ. Preview: Janssen, Penn State Prof. Seek Relief
• Credit Bureaus Fight Bid To Add Plaintiffs, Claims To Suit
• Mastectomy Bras Found Not Distinct Enough To Be Duty-Free
• AI-Assisted Arbitration Needs Safeguards To Ensure Fairness
• Life Sciences Group Of The Year: Goodwin
• Minn. State Sens. Introduce Medical Psilocybin Bill
• Taxation With Representation: Linklaters, Wilson Sonsini
• 121-Year-Old Ruling Still A Shot In The Arm For Vax Mandates
• IRhythm Investors Say 2021 Goldman Ruling Doesn't Bar Cert.
• Health Plans Lack Expert In Avandia MDL, 3rd Circ. Told
• Justices Told 'Skinny Label' Case Puts Generic Drugs At Risk
• Squires Grants 3 IPRs, Denies 10, Marks RPI Order Informative
• Chancery Asked To OK $7.6M Deal To End $1.5B De-SPAC Row
• Trans Care Enforcement Landscape Is Evolving Quickly
• Boston Scientific Wins Toss Of Spinal Device Suit
• Kenvue Can't Duck Texas AG's Tylenol Autism Suit
• $200M Antitrust Deal Can Shield Drugmakers In States' Claims
• Life Sciences Group Of The Year: Covington
• Hawaii Officials Fight Claim That Hemp Law Violates Farm Bill
• Feds Back Pharma In 340B Contract Pharmacy Disputes
• Playing Piano Makes Me A Better Lawyer
• Online Abortion Pill Provider Illegally Ships To Texas, AG Says
• White House Cites Fraud, Freezes $259M In Minn. Medicaid
• Fed. Circ. Gene Therapy Ruling Gives Rare Eligibility Clarity
• $17.9M Drug Price-Fixing Deal Advances Despite Objections
• Birth Control Shot Plaintiffs Lose Mid-Case Appeal Bid In Del.
• NJ Judge Trims J&J And Neutrogena Benzene Suit
• 9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case
• Philly Says PBMs Can't Exit Suit Over Opioid Crisis
• Hagens Berman Fights Fee Demand Amid Misconduct Claims
• Life Sciences Group Of The Year: Davis Polk
• Taft Adds 5-Person IP Team From McAndrews Held
• Budtender Alleges Dispensary Gives Tips To Managers
• Moderna's Damages Expert Limited In March Patent Trial
• Novo's $2.1B Vivtex Deal Boosts Obesity Drug Pipeline
• 9th Circ. Grants Atty Fee Appeal In Eye Drop Pricing Suit
• Ariz., Calif. Lead Suit Over 'Senseless' HHS Vaccine Overhaul
• Ex-Med School Dean Claims Fla. College Broke Work Contract
• Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit
• 6th Circ. Affirms Dismissal Of Sotera Toxic Gas Investor Suit
• Lindis Decries Erasing $50M Verdict Over Inequitable Conduct
• High Court Won't Stay Dow Corning Breast Implant Fund Row
• Novo Nordisk Wants Expert Cut From Hospital Insulin Pen Suit
• Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules
• Philips Unit Escapes CPAP Machine Whistleblower Case
• Biotech Co. Moves To Dismiss LSD Trade Secret Suit
• Suit Says Ex-Medco CFO Inflated Company's Value Before Sale
• 3 Cases Highlight SEC Distinction Between Exec, Co. Liability
• Headache-Focused Biotech Raises $130M In Series A Round
• AI-Generated Doc Ruling Guides Attys On Privilege Risks
• Life Sciences Group Of The Year: Gibson Dunn
• AstraZeneca Drug Price Challenge Falls Short In Hawaii
• Mintz Lands IP Pro From Wilson Sonsini In San Francisco
• 8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims
• Judge Tosses Fitch Suit Against Ex-Client In Malpractice Row
• Bayer Sues J&J Over Alleged False Cancer Drug Claims
• DC Circ. Talks Sharks, Moats In Vertex HHS Kickback Appeal
• Zynex Faces Securities Suit Following Arrest Of Former Execs
• Synthego Urges Justices To Reject AI Bait In CRISPR Case
• CBP Clears Redesigned Tourniquet Imports After IP Ban
• Corcept Mischaracterized Drug Approval Odds, Investor Says
• Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit
• Justices Want Natera's Take On CareDx's False Ad Petition
• Asthma Biotech Generate Biomedicines Eyes $400M IPO
• The Law Firm Merger Diaries: Leadership Strategy After Day 1
• Life Sciences Group Of The Year: Ropes & Gray
• Hims & Hers Misleads With GLP-1 Claims In Ads, Court Told
• Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy
• BioNTech Says Moderna's New COVID Vax Infringes Its IP
• Dallas Jury Finds Ex-NFL Player Ran $328M Medicare Scheme
• Fertility Doctors Beat Patient's Embryo Loss Case
• Fed. Circ. Unwinds Ineligibility Ruling For Gene Therapy IP
• Record FCA Recoveries Signal Intensified Healthcare Focus
• Fed. Circ. In Jan.: On The Validity Of Expert Testimony
• Merck Wants Out Of Ex-Workers' Wage, ADA Suit
• Chinese Chemical Imports Evading Duties, Commerce Says
• Calif.'s Civility Push Shows Why Professionalism Is Vital
• Beasley Allen Can't Pause NJ Talc DQ Order, Judge Rules
• Judge Says Texas Can't Enforce Optometry Anti-Steering Law
• US Hits Pill Capsules From 4 Countries With Duty Orders
• Taxation With Representation: Freshfields, Simpson Thacher
• Judge Denies Mylan And Aurobindo's Bid To Escape Trial
• Texas Suit Says Sanofi Paid Kickbacks For Prescriptions
• Justices Urged To Bar Passive Infringement For Skinny Labels
• Judge Affirms Literal Infringement In Ravgen's $57M Jury Win
• Red State AGs Back La. Bid To Halt Eased Abortion Pill Rules
• She Has A Point: Dechert's Kassie Helm
• Squires Accepts 8 PTAB Cases, Walks Back 7 Merits Referrals
• Pharma Group Asks 1st Circ. To Ax RI's 340B Drug Price Law
• Hims & Hers Buying Eucalyptus For Up To $1.15B
• Scientist Must Give Splenda Maker Emails With In-House Attys
• A Potential Shift In FDA's Approach To Drug Trial Design
• Fed. Circ. Won't Revive Corcept's Drug Patent Feud
• Harvard Docs Get Censored Articles Permanently Restored
• AstraZeneca Prevails In Whistleblower Suit 9th Circ. Revived
• Trump Orders Weedkiller Glyphosate Production Hike
• Mylan Investors Ink $60M Deal In Quality Control Suit
• Trivia Competition Makes Me A Better Lawyer
• BakerHostetler Adds Contaminants Pro From DLA Piper
• Genetic Testing Co.'s Acquisition Draws Privacy Suit
• Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed
• Axsome Blocks Sleep Disorder Drug Generic Until 2040
• RFK Jr.-Founded Group Seeks Role In Vaccine Lawsuit
• NY Judge Trims Umbilical Cord Blood Co. Investor Suit
• J&J Unit Appeals $442M Catheter Antitrust Loss To 9th Circ.
• What FDA Guidance Means For Future Of Health Software
• FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine
• Federal Preemption In AI And Robotics Is Essential
• Levi & Korsinsky To Lead Novo Nordisk Investor Class Action
• Law School's Missed Lessons: What Cross-Selling Truly Takes
• Paul Hastings Adds Cooley Atty As Life Science Deals Leader
• Judge Trims Moderna's Defenses In COVID Patent Suit
• Judge Rips Drugmakers' Borderline 'Disingenuous' Appeal Bid
• Union Says Express Scripts Diverted Billions In Kickback Fees
• Squires Ends IPR After ITC Judge Rejects Validity Challenge
• Cohen Milstein To Rep Perrigo Investors In Formula Biz Suit
• McGuireWoods Adds Sidley Private Equity Pro In Los Angeles
• J&J Fights Beasley Allen's Bid To Pause Talc DQ Ruling
• Edwards Sued In Chancery Over $300M Heart Valve Earn-Out
• Philips Settles Suit Over Sleep Machine Starting Home Fire
• RFK Jr. Taps Ex-Jones Day Atty For FDA Senior Counselor
• States' Generic Drugs Antitrust Case Headed Toward Trial
• Chewy Settles Antitrust Claims Over Elanco Flea & Tick Meds
• Docs Urge Judge To Block CDC's Childhood Vaccine Changes
• Reed Smith Nabs Ex-WilmerHale Capital Markets Pro
• Iowa AG Urges 8th Circ. To Unblock Parts Of State PBM Law
• Drafting Tech Patents After USPTO's Eligibility Memos
• How State FCA Activity May Affect Civil Fraud Enforcement
• FDA Removes Boxed Warnings From HRT Products
• Judges On AI: Practical Use Cases In Chambers
• How Attorneys Are Handling A Patent Review 'Sea Change'
• J&J Hit With $250K Verdict In 2nd Philly Talc Trial
• CareDx Seeks High Court Review Of $45M False Ad Case
• Prenatal Testing Co. Missed Fatal Condition, Couple Say
• FTC's PBM Case Paused For More Deal Talks
• Assessing Compliance Risks Around TrumpRx Participation
• Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case
• USPTO Initiatives May Bolster SEP Litigation In The US
• Astellas Gets $120M From Zydus In Bladder Drug Deal
• Goodwin Expands Healthcare Team With Ex-Reed Smith Atty
• Regeneron, Samsung Bioepis Settle Eye Med Patent Claims
• Trail Running Makes Me A Better Lawyer
• McKesson Freed From Opioid Death Suit By Ga. Panel
• AbbVie Sues Medicaid, HHS Over Botox Fair Price Controls
• Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute
• Luxottica Franchisee Gets Another Shot At Antitrust Claims
• Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now
• NY Judge Rejects Bid To Stop SD Action Against Abortion Ads
• Predicting Actual Impact From CDC's New Vaccine Guidance
• Supreme Court Sets April Argument For 'Skinny Label' Case
• 7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal
• Shkreli Can't Add Wu-Tang Members To Fight With Crypto Co.
• Beasley Allen Wants Talc DQ Paused Pending High Court Appeal
• AI Scientific Discovery Order Implications For Life Sciences
• What Rescheduling Means For Cannabis Labels, Marketing
• Tips From Del. Decision Nixing Major Earnout Damages Award
• Trans Health And Pediatric Groups Challenge FTC Subpoenas
• Judge Limits Insurers' Exposure in Opioid Coverage Fight
• GSK, Teva Settle 'Skinny Label' Heart Medication Suit
• Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps
• Lutnick Rules Out Creating Value-Based Fees For Patents
• USPTO's New Patentability Focus Helps Emerging Tech
• Lipid Testing Patents Recite Laws Of Nature, Judge Says
• Apple Again Pushes To Escape Masimo's $634M IP Verdict
• Pa. Hospital Settles Ex-Worker's ADA Suit Over CBD Gummy
• Judge Questions Timing Of Case Against Harvard Researcher
• Astellas Gets $90M From Lupin In Myrbetriq Patent Deal
• Norton Rose Hires Cooley Life Sciences Duo In DC
• Malpractice Claim Assignability Continues To Divide Courts
• Whooping Cough-Focused Biotech Wraps $115M Fundraise
• Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages
• Defendant Mix-Up Ends Biotech FCA Suit, For Now
• Italian Biathlete Lodges Appeal Of Olympic Doping Ban
• Fed. Circ. Sends Blood Pump Patent Fight Back To Mass.
• Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1
• Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.
• High Court Asked To Take Up Malpractice Case Against Akin
• Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy
• Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit
• Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case
• HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight
• NJ Judge Tosses Pacira Investor Suit Over Patent Loss
• Arizona Abortion Restrictions Found Unconstitutional
• PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test
• 3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study
• TPG Hid Exactech Defects To Dodge Liability, Trust Alleges
• SEC Alleges Pharma Co. Misled Investors About Cancer Drug
• Unpacking Dormant Commerce Clause Cannabis Circuit Split
• CFIUS Must Adapt To Current Foreign Investment Realities
• Beasley Allen Disqualified From NJ Talc Multicounty Litigation
• Insulet Gets $14.9M Fee Award For Trade Secret Trial Win
• FLSA Does Not Bar Claim Waivers, Wash. Judge Says
• HHS Ends 340B Drug Rebate Pilot After Legal Challenge
• NYAG's Insider Trading Case A Power Grab, Judge Told
• Full Fed. Circ. Won't Rethink Heart Monitor Patent Claim Ax
• Judge Affirms Health Cos.' Sanctions For Witness Omission
• David Protein Gets Ingredient Supply Antitrust Claims Tossed
• Patent Co., AI Research Firm Join Forces In $150M Deal
• Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'
• Utah's AI Prescription Renewal Pilot Could Inform Policy
• Medtronic Hit With $382M Antitrust Verdict Over Bundling
• Yale Health System Seeks $4.1M Coverage For Transplant
• Trump Admin Finalizes Rule Facilitating Federal Worker Firings
• Covington, Davis Polk Lead Eikon's Upsized $381M IPO
• Ramped Up Psychedelic Production Carries Opportunity, Risk
• Teaching Logic Makes Me A Better Lawyer
• Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO
• 'Careless Or Disingenuous': Judge Rips CareFirst Rethink Bid
• Medtronic Owes $381M For Antitrust 'War Games,' Jury Told
• Fed. Circ. Leans Toward Vacating $12.7M Copyright Award
• Class Attys In Del. Northwest Biotherapeutics Praise Deal
• New Biotech Nat'l Security Controls May Have Blunted Impact
• Teva Wins 1st Paragard IUD Bellwether Trial
• Walgreens Says Audio Recording Refutes Shareholders' Claim
• Teva Fights Class Cert. Bid In Effexor Antitrust Case
• From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination
• Stem-Cell Drug Developer PrimeGen Inks $1.5B SPAC Merger
• Law School's Missed Lessons: Practicing Resilience
• Takeaways From The DOJ Fraud Section's 2025 Year In Review
• Whoop Nabs Block On Chinese Co.'s Health-Tracker Products
• Drugmakers Say Hagens Berman Responsible For Costs
• Fertility Clinic Says Doctors Lured Staff To New Practice
• Ex-Hogan Lovells Regulatory Atty Moves To Honigman In DC
• Drugmaker Claims Stake In La. Mail-Order Abortion Meds Row
• Express Scripts Makes 'Fundamental Changes' In FTC Deal
• ImmunityBio Stockholder Targets Soon-Shiong In Chancery
• Squires And Stewart's Patent Office, By The Numbers
• Medtronic's Bundling Isn't Anticompetitive, Prof Tells Jury
• Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK
• Trump Admin Sued Over 'Pay-To-Play' Gold Card Program
• Upshot Of 'Skinny Label' Case May Go Beyond Pharma
• Medical Transport Co. Misclassified Drivers, Suit Says
• Novartis, Sandoz Face New Generic-Drug Price-Fixing Suit
• Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says
• Amway Looks To Sidestep Gut Drink Trademark Fight In NC
• Alston & Bird Adds Healthcare Regulatory Pro From Goodwin
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• 'Terumo Knew' Of Dangerous Emissions, Jury Told
• 'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit
• Monthly Merger Review Snapshot
• PTAB Sinks Samsung Challenge To Ouraring Patent
• Assessing Factors Behind Biosimilar Uptake And Competition
• 1st Circ. Judge Wary Of Boston Bid To Revive PBM Opioid Suit
• Traditional FCA Enforcement Surges Amid Shifting Priorities
• DLA Piper Adds Ex-Cooley Atty To Lead N. Calif. Practice
• Mintz Adds Winston & Strawn ITC Practice Co-Leader In DC
• NYC Bar Opinion Warns Attys On Use Of AI Recording Tools
• Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal
• The Biz Court Digest: Dispatches From Utah's Newest Court